658 related articles for article (PubMed ID: 19639293)
1. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.
Stone TW; Ceruti S; Abbracchio MP
Handb Exp Pharmacol; 2009; (193):535-87. PubMed ID: 19639293
[TBL] [Abstract][Full Text] [Related]
2. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Chen JF; Chern Y
Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.
Chen JF; Sonsalla PK; Pedata F; Melani A; Domenici MR; Popoli P; Geiger J; Lopes LV; de Mendonça A
Prog Neurobiol; 2007 Dec; 83(5):310-31. PubMed ID: 18023959
[TBL] [Abstract][Full Text] [Related]
4. Purinergic receptors in gastrointestinal inflammation.
Kolachala VL; Bajaj R; Chalasani M; Sitaraman SV
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G401-10. PubMed ID: 18063703
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.
Bruno V; Battaglia G; Copani A; D'Onofrio M; Di Iorio P; De Blasi A; Melchiorri D; Flor PJ; Nicoletti F
J Cereb Blood Flow Metab; 2001 Sep; 21(9):1013-33. PubMed ID: 11524608
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective role of adenosine in the CNS.
Wardas J
Pol J Pharmacol; 2002; 54(4):313-26. PubMed ID: 12523485
[TBL] [Abstract][Full Text] [Related]
7. Different roles of adenosine A1, A2A and A3 receptors in controlling kainate-induced toxicity in cortical cultured neurons.
Rebola N; Rodrigues RJ; Oliveira CR; Cunha RA
Neurochem Int; 2005 Oct; 47(5):317-25. PubMed ID: 16011860
[TBL] [Abstract][Full Text] [Related]
8. Adenosine and brain ischemia.
Rudolphi KA; Schubert P; Parkinson FE; Fredholm BB
Cerebrovasc Brain Metab Rev; 1992; 4(4):346-69. PubMed ID: 1486019
[TBL] [Abstract][Full Text] [Related]
9. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
[TBL] [Abstract][Full Text] [Related]
10. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors.
Castillo A; Tolón MR; Fernández-Ruiz J; Romero J; Martinez-Orgado J
Neurobiol Dis; 2010 Feb; 37(2):434-40. PubMed ID: 19900555
[TBL] [Abstract][Full Text] [Related]
11. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
Abbracchio MP; Cattabeni F
Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415
[TBL] [Abstract][Full Text] [Related]
12. Adenosine receptor control of cognition in normal and disease.
Chen JF
Int Rev Neurobiol; 2014; 119():257-307. PubMed ID: 25175970
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A2A receptors and Parkinson's disease.
Morelli M; Carta AR; Jenner P
Handb Exp Pharmacol; 2009; (193):589-615. PubMed ID: 19639294
[TBL] [Abstract][Full Text] [Related]
14. Involvement of P2 receptors in the growth and survival of neurons in the CNS.
Franke H; Illes P
Pharmacol Ther; 2006 Mar; 109(3):297-324. PubMed ID: 16102837
[TBL] [Abstract][Full Text] [Related]
15. [Neuroprotective mechanisms of adenosine action on CNS neurons].
Zalewska-Kaszubska J
Neurol Neurochir Pol; 2002; 36(2):329-36. PubMed ID: 12046508
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in adenosine A2A receptor ligands.
Cristalli G; Müller CE; Volpini R
Handb Exp Pharmacol; 2009; (193):59-98. PubMed ID: 19639279
[TBL] [Abstract][Full Text] [Related]
17. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
18. On the hypes and falls in neuroprotection: targeting the NMDA receptor.
Villmann C; Becker CM
Neuroscientist; 2007 Dec; 13(6):594-615. PubMed ID: 17911221
[TBL] [Abstract][Full Text] [Related]
19. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
20. Highlights on the development of A(2A) adenosine receptor agonists and antagonists.
Cristalli G; Cacciari B; Dal Ben D; Lambertucci C; Moro S; Spalluto G; Volpini R
ChemMedChem; 2007 Mar; 2(3):260-81. PubMed ID: 17177231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
